University Hospital Freiburg

Freiburg im Breisgau 79106

2 studies enrolling now · 14 studies all time

What they study most

Age Related Macular Degeneration, Ankle Fractures, Candidemia, Chronic Hepatitis C Infection, Colostomy, Distal Radius Fracture, Duchenne Muscular Dystrophy, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Focal Epilepsy, Fungal Infection, Hepatitis C, Chronic

Studies at this site

• Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib — Recruiting now
• An Open-label Study of XEN1101 in Epilepsy — Enrolling by invitation
• Go Fit Fast, Recovery Trajectory Using PROMIS®, Linking PROMIS® — Running, not enrolling
• Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD) — Completed
• Protective Ventilation With High Versus Low PEEP During One-lung Ventilation for Thoracic Surgery — Completed
• A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression — Completed
• PArtial REbreathing for Migraine With Aura 1 — Stopped early
• A Phase 3 Study to Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD — Completed
• Patients 60 Years and Older Suffering From Mandibular Fractures Registry — Stopped early
• Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis — Completed
• Efficacy, Safety and Tolerability of AG013 in Oral Mucositis Compared to Placebo When Administered Three Times Per Day — Stopped early
• A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C — Completed
• A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C — Completed
• Multi-National Phase III Vitala™ 12-Hour Wear Test — Completed